相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy
Bhagirathbhai Dholaria et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Richard T. Maziarz et al.
BONE MARROW TRANSPLANTATION (2021)
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
Antonio M. Jimenez Jimenez et al.
BONE MARROW TRANSPLANTATION (2021)
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
Claudio Cerchione et al.
FRONTIERS IN ONCOLOGY (2021)
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Alexander E. Perl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
Evan C. Chen et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Zachariah DeFilipp et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz et al.
BLOOD (2020)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A US Food and Drug Administration Systematic Analysis
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2020)
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL
Neeraj Saini et al.
BLOOD (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan et al.
LANCET ONCOLOGY (2020)
How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT
Olaf Penack et al.
BLOOD ADVANCES (2020)
A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation
Amir T. Fathi et al.
BLOOD (2020)
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Betul Oran et al.
BLOOD ADVANCES (2020)
Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations
Amandeep Salhotra et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
Daniel A. Pollyea et al.
LEUKEMIA (2019)
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy
Zachariah DeFilipp et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review
Zabih Warraich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
How I treat Philadelphia chromosome- positive acute lymphoblastic leukemia
Farhad Ravandi
BLOOD (2019)
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions
Vivek A. Upadhyay et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia
Paul A. Carpenter et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
C. D. DiNardo et al.
LEUKEMIA (2016)
Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation
Zachariah DeFilipp et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
P. Tsirigotis et al.
BONE MARROW TRANSPLANTATION (2016)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Gebel et al.
CANCER (2016)
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors. Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Zachariah DeFilip et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL
Farhad Ravandi et al.
BLOOD ADVANCES (2016)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
Gaku Oshikawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase 1/2 Study of Nilotinib Prophylaxis After Allogeneic Stem Cell Transplantation in Patients With Advanced Chronic Myeloid Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Avichai Shimoni et al.
CANCER (2015)
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Eolia Brissot et al.
HAEMATOLOGICA (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
A. P. Im et al.
LEUKEMIA (2014)
CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a test dose Strategy to Target Busulfan Exposure
Ravi Vij et al.
BLOOD (2014)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
H. Pfeifer et al.
LEUKEMIA (2013)
Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
Philippe Armand et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation Frequency and Clinicopathologic Features
Keyur P. Patel et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
Anna M. Jankowska et al.
BLOOD (2011)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Robin Foa et al.
BLOOD (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
W-C Chou et al.
LEUKEMIA (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
Saman Abbas et al.
BLOOD (2010)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final resullts of the CSTIBES02 trial
Josep-Maria Ribera et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Katharina Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Low-Dose Azacitidine After Allogeneic Stem Cell Transplantation for Acute Leukemia
Elias Jabbour et al.
CANCER (2009)
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria et al.
BLOOD (2007)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
Paul A. Carpenter et al.
BLOOD (2007)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
分享论文
